ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Healthcare CMO Market Analysis Report 2025: Ongoing R&D Investments and Launch of Novel, Regulatory-Approved Contract Manufacturing Solutions - Forecast to 2029 - ResearchAndMarkets.com

The "Healthcare CMO Market: 2025 Edition" report has been added to ResearchAndMarkets.com's offering.

The global healthcare CMO market was valued at US$145.83 billion in 2023, and is predicted to grow to US$291.25 billion in 2029. The global healthcare CMO market is determined to grow at a CAGR of 12.22% over the forecasted period of 2024-2029.

Global healthcare CMO market is fragmented. There is a wide array of CMOs ranging from large multinational corporations to small and mid-sized firms specializing in niche areas or regional markets. The key players in the healthcare CMO market provides a detailed competitive landscape and focus on launching novel products with the necessary approvals. There is a continuing need for research and development, which is still a key strategy among market players.

The healthcare CMO market has experienced significant growth over the years primarily due to the increasing demand for pharmaceutical and biopharmaceutical products, spurred by the rising prevalence of chronic diseases and the aging global population. Also, the trend of pharmaceutical companies outsourcing manufacturing to CMOs to reduce costs and focus on core competencies has contributed significantly to market expansion.

Advancements in manufacturing technologies and processes have also enabled CMOs to offer high-quality, scalable, and cost-effective production solutions. Other significant trends include escalating role of artificial intelligence technology, personalized medicine, sustainability and green manufacturing, advanced manufacturing technologies, expansion in cell and gene therapy etc.

The global healthcare CMO market is divided into four regions: North America, Europe, Asia-Pacific, and ROW. North America accounted for the maximum share of the global market in 2023. The market in North America is being driven by the region's increased emphasis on drug discovery and manufacturing outsourcing. The region is increasing its use of scientific exploration of disease mechanisms leading to the discovery and development of agents. Pre-clinical testing is an important stage in pharmaceutical research. At this stage, several tests are performed to determine whether a drug is ready for clinical trials.

Asia-Pacific is predicted to grow at a significantly high rate during the forecasted period because the region offers substantial cost advantages, including lower labor and operational costs, making it an attractive hub for manufacturing activities. Many countries in Asia-Pacific, such as China and India, have invested heavily in developing their pharmaceutical and biotechnology infrastructure, providing state-of-the-art facilities and expertise.

Secondly, the region has a large and growing population, increasing the demand for healthcare services and pharmaceutical products. This demographic shift is driving local and international pharmaceutical companies to expand their presence in Asia-Pacific. Additionally, supportive government policies, including favorable regulations and incentives for foreign investment, have created a conducive environment for the growth of CMOs.

Market Segmentation Analysis:

By Type: The report identifies two segments on the basis of type: Pharmaceutical and Medical Device. The pharmaceuticals manufacturing segment acquired majority of share in the market in 2023 and is expected to grow at the fastest rate in the market during the forecast period, owing to increasing prevalence of chronic diseases and the rising global demand for complex drugs has driven pharmaceutical companies to outsource manufacturing to CMOs. Additionally, the surge in the development of complex biologics, personalized medicines, and specialty drugs necessitates advanced manufacturing capabilities, which many CMOs possess.

Further, the ongoing advancements in pharmaceutical manufacturing technologies, coupled with the trend towards outsourcing, are expected to sustain and accelerate the growth of the pharmaceuticals manufacturing segment in the healthcare CMO market. Pharmaceutical CMO segment is further divided into two segments on the basis of service: Active Pharmaceutical Ingredients (API) and Others.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic had a positive demand shock, attributable to the increasing number of biopharmaceutical services provided to CMOs. CMOs invested in and acquired facilities in order to be ready for high-volume production units. This pandemic has proven to be an era of exponential growth in facility and bioprocessing units to have a higher output for increased and continuous supply.

Vaccine development and manufacturing activity in the healthcare CMO market has increased during pandemic, owing primarily to the industry's response to the COVID-19 pandemic. This expansion is expected to continue in the coming years as well. CMOs have made capacity and resource investments to address supply chain challenges. The CMO industry has seen an increase in modular construction and expansion, investments in cutting-edge technology, and process intensification strategies. Furthermore, many CMOs expanded their capabilities in new modalities such as [messenger RNA] mRNA and cell and gene therapy, which would drive the growth of the market during the post COVID period.

Competitive Landscape:

These major players have been implementing novel strategies to expand market prospects in the coming years. On July 11, 2023, Recipharm Opens New Analytical Laboratory in Bangalore, India, to Increase Global Testing Capabilities for Nitrosamines, Extractables, Leachables, and Elemental Impurity Testing. 5,000 Sq Ft. Laboratory would support Recipharm's existing analytical capacity to support biotech and pharma customers in the Research and Development of Oral Solids, Drug Delivery, Inhalation, Vaccine, and Injectables with Full cGMP Compliance.

Market Dynamics

Growth Drivers

  • Surging Geriatric Population
  • Rising Healthcare Expenditure
  • Increasing Spread of Chronic Diseases
  • Escalating Demand for Generic Drugs
  • Cost Efficiency
  • Complexity of Biologics Manufacturing
  • Increasing Demand for Active Pharmaceutical Ingredient (API)

Challenges

  • Regulatory Compliance
  • Dependent on Patents, Copyrights, Trademarks and Trade Secrets

Market Trends

  • Escalating Role of Artificial Intelligence Technology
  • Personalized Medicine
  • Sustainability and Green Manufacturing
  • Advanced Manufacturing Technologies
  • Expansion in Cell and Gene Therapy
  • Exploration of Alternative Expression Systems
  • Growing Inclination Towards Herbal Products

Global Market Analysis

Global Healthcare CMO Market: An Analysis

  • Global Healthcare CMO Market: An Overview
  • Global Healthcare CMO Market by Value
  • Global Healthcare CMO Market by Type (Pharmaceutical and Medical Device)
  • Global Healthcare CMO Market by Region (North America, Europe, Asia Pacific, and rest of the World (ROW)

Global Healthcare CMO Market: Type Analysis

  • Global Healthcare CMO Market by Type: An Overview
  • Global Pharmaceutical CMO Market by Value
  • Global Pharmaceutical CMO Market by Service (Active Pharmaceutical Ingredients (API) and Others)
  • Global Medical Devices CMO Market by Value

Global Pharmaceutical CMO Market: Service Analysis

  • Global Pharmaceutical CMO Market by Service: An Overview
  • Global Active Pharmaceutical Ingredients (API) CMO Market by Value
  • Global Other Pharmaceuticals CMO Market by Value

Key Players in the Global Healthcare CMO Market

  • Catalent Pharma Solutions, Inc.
  • Samsung Biologics Co. Ltd.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim GmbH
  • Integer Holdings Corporation
  • Piramal Enterprises Limited
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Fareva Group
  • Symbiosis Pharmaceutical Services
  • Curia
  • Cytovance Biologics

For more information about this report visit https://www.researchandmarkets.com/r/t6x98l

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.